|
1
|
Neville BW and Day TA: Oral cancer and
precancerous lesions. CA Cancer J Clin. 52:195–215. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pulte D and Brenner H: Changes in survival
in head and neck cancers in the late 20th and early 21st century: A
period analysis. Oncologist. 15:994–1001. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hirano T, Yasukawa K, Harada H, Taga T,
Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K,
Iwamatsu A, et al: Complementary DNA for a novel human interleukin
(BSF-2) that induces B lymphocytes to produce immunoglobulin.
Nature. 324:73–76. 1986. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yuzhalin A and Kutikhin A: Interleukins in
Cancer Biology: Their Heterogeneous Role. Elsevier; 2014
|
|
5
|
Heinrich PC, Behrmann I, Haan S, Hermanns
HM, Müller-Newen G and Schaper F: Principles of interleukin
(IL)-6-type cytokine signalling and its regulation. Biochem J.
374:1–20. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guo Y, Xu F, Lu T, Duan Z and Zhang Z:
Interleukin-6 signaling pathway in targeted therapy for cancer.
Cancer Treat Rev. 38:904–910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang YF, Chang SY, Tai SK, Li WY and Wang
LS: Clinical significance of interleukin-6 and interleukin-6
receptor expressions in oral squamous cell carcinoma. Head Neck.
24:850–858. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen CJ, Sung WW, Lin YM, Chen MK, Lee CH,
Lee H, Yeh KT and Ko JL: Gender difference in the prognostic role
of interleukin 6 in oral squamous cell carcinoma. PLoS One.
7:e501042012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Duffy SA, Taylor JM, Terrell JE, Islam M,
Li Y, Fowler KE, Wolf GT and Teknos TN: Interleukin-6 predicts
recurrence and survival among head and neck cancer patients.
Cancer. 113:750–757. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jinno T, Kawano S, Maruse Y, Matsubara R,
Goto Y, Sakamoto T, Hashiguchi Y, Kaneko N, Tanaka H, Kitamura R,
et al: Increased expression of interleukin-6 predicts poor response
to chemoradiotherapy and unfavorable prognosis in oral squamous
cell carcinoma. Oncol Rep. 33:2161–2168. 2015.PubMed/NCBI
|
|
11
|
Mojtahedi Z, Khademi B, Hashemi SB, Abtahi
SM, Ghasemi MA, Fattahi MJ and Ghaderi A: Serum interleukine-6
concentration, but not interleukine-18, is associated with head and
neck squamous cell carcinoma progression. Pathol Oncol Res.
17:7–10. 2011. View Article : Google Scholar
|
|
12
|
Cohen S, Bruchim I, Graiver D, Evron Z,
Oron-Karni V, Pasmanik-Chor M, Eitan R, Bernheim J, Levavi H,
Fishman A, et al: Platinum-resistance in ovarian cancer cells is
mediated by IL-6 secretion via the increased expression of its
target cIAP-2. J Mol Med Berl. 91:357–368. 2013. View Article : Google Scholar
|
|
13
|
Pu YS, Hour TC, Chuang SE, Cheng AL, Lai
MK and Kuo ML: Interleukin-6 is responsible for drug resistance and
anti-apoptotic effects in prostatic cancer cells. Prostate.
60:120–129. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yan HQ, Huang XB, Ke SZ, Jiang YN, Zhang
YH, Wang YN, Li J and Gao FG: Interleukin 6 augments lung cancer
chemotherapeutic resistance via ataxia-telangiectasia
mutated/NF-kappaB pathway activation. Cancer Sci. 105:1220–1227.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Suchi K, Fujiwara H, Okamura S, Okamura H,
Umehara S, Todo M, Furutani A, Yoneda M, Shiozaki A, Kubota T, et
al: Overexpression of interleukin-6 suppresses cisplatin-induced
cytotoxicity in esophageal squamous cell carcinoma cells.
Anticancer Res. 31:67–75. 2011.PubMed/NCBI
|
|
16
|
Poth KJ, Guminski AD, Thomas GP, Leo PJ,
Jabbar IA and Saunders NA: Cisplatin treatment induces a transient
increase in tumorigenic potential associated with high
interleukin-6 expression in head and neck squamous cell carcinoma.
Mol Cancer Ther. 9:2430–2439. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lawrence MS, Sougnez C, Lichtenstein L,
Cibulskis K, Lander E, Gabriel SB, Getz G, Ally A, Balasundaram M,
Birol I, et al: Cancer Genome Atlas Network: Comprehensive genomic
characterization of head and neck squamous cell carcinomas. Nature.
517:576–582. 2015. View Article : Google Scholar
|
|
18
|
Husvik C, Bryne M and Halstensen TS: c-Jun
N-terminal kinase negatively regulates epidermal growth
factor-induced cyclooxy-genase-2 expression in oral squamous cell
carcinoma cell lines. Eur J Oral Sci. 117:663–668. 2009. View Article : Google Scholar
|
|
19
|
Haddad R, Wirth L and Posner M: Emerging
drugs for head and neck cancer. Expert Opin Emerg Drugs.
11:461–467. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aguirre-Gamboa R, Gomez-Rueda H,
Martínez-Ledesma E, Martínez-Torteya A, Chacolla-Huaringa R,
Rodriguez- Barrientos A, Tamez-Peña JG and Treviño V: SurvExpress:
An online biomarker validation tool and database for cancer gene
expression data using survival analysis. PLoS One. 8:e742502013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sato J, Ohuchi M, Abe K, Satoh T, Abe T,
Yamazaki Y, Satoh A, Notani K and Kitagawa Y: Correlation between
salivary interleukin-6 levels and early locoregional recurrence in
patients with oral squamous cell carcinoma: Preliminary study. Head
Neck. 35:889–894. 2013. View Article : Google Scholar
|
|
22
|
Yadav A, Kumar B, Datta J, Teknos TN and
Kumar P: IL-6 promotes head and neck tumor metastasis by inducing
epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling
pathway. Mol Cancer Res. 9:1658–1667. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang L, Yang J, Qian J, Li H, Romaguera
JE, Kwak LW, Wang M and Yi Q: Role of the microenvironment in
mantle cell lymphoma: IL-6 is an important survival factor for the
tumor cells. Blood. 120:3783–3792. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Borsellino N, Bonavida B, Ciliberto G,
Toniatti C, Travali S and D'Alessandro N: Blocking signaling
through the Gp130 receptor chain by interleukin-6 and oncostatin M
inhibits PC-3 cell growth and sensitizes the tumor cells to
etoposide and cisplatin-mediated cytotoxicity. Cancer. 85:134–144.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lou W, Ni Z, Dyer K, Tweardy DJ and Gao
AC: Interleukin-6 induces prostate cancer cell growth accompanied
by activation of stat3 signaling pathway. Prostate. 42:239–242.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ
and Li LZ: Autocrine production of interleukin-6 confers cisplatin
and paclitaxel resistance in ovarian cancer cells. Cancer Lett.
295:110–123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ara T, Nakata R, Sheard MA, Shimada H,
Buettner R, Groshen SG, Ji L, Yu H, Jove R, Seeger RC, et al:
Critical role of STAT3 in IL-6-mediated drug resistance in human
neuroblastoma. Cancer Res. 73:3852–3864. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu Y, Li PK, Li C and Lin J: Inhibition
of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in
human liver cancer cells. J Biol Chem. 285:27429–27439. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gougelet A, Mansuy A, Blay JY, Alberti L
and Vermot-Desroches C: Lymphoma and myeloma cell resistance to
cytotoxic agents and ionizing radiations is not affected by
exposure to anti-IL-6 antibody. PLoS One. 4:e80262009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Arinobu Y, Atamas SP, Otsuka T, Niiro H,
Yamaoka K, Mitsuyasu H, Niho Y, Hamasaki N, White B and Izuhara K:
Antagonistic effects of an alternative splice variant of human
IL-4, IL-4delta2, on IL-4 activities in human monocytes and B
cells. Cell Immunol. 191:161–167. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Alberti L, Bachelot T, Duc A, Biota C and
Blay JY: A spliced isoform of interleukin 6 mRNA produced by renal
cell carcinoma encodes for an interleukin 6 inhibitor. Cancer Res.
65:2–5. 2005.PubMed/NCBI
|
|
32
|
Bihl MP, Heinimann K, Rüdiger JJ,
Eickelberg O, Perruchoud AP, Tamm M and Roth M: Identification of a
novel IL-6 isoform binding to the endogenous IL-6 receptor. Am J
Respir Cell Mol Biol. 27:48–56. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yatsenko OP, Silkov AN, Khrapov EA,
Filipenko ML, Kozlov VA and Sennikov SV: Tissue-specific expression
of splice variants of human IL-4 and IL-6 gene mRNA. Bull Exp Biol
Med. 152:329–332. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stransky N, Egloff AM, Tward AD, Kostic
AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C,
McKenna A, et al: The mutational landscape of head and neck
squamous cell carcinoma. Science. 333:1157–1160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jansson MD and Lund AH: MicroRNA and
cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rokavec M, Wu W and Luo JL: IL6-mediated
suppression of miR-200c directs constitutive activation of
inflammatory signaling circuit driving transformation and
tumorigenesis. Mol Cell. 45:777–789. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ceppi P, Mudduluru G, Kumarswamy R, Rapa
I, Scagliotti GV, Papotti M and Allgayer H: Loss of miR-200c
expression induces an aggressive, invasive, and chemoresistant
phenotype in non-small cell lung cancer. Mol Cancer Res.
8:1207–1216. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M,
Zhang W, Chen W, Pan C, Liu Q, et al: miR-200b and miR-15b regulate
chemotherapy-induced epithelial-mesenchymal transition in human
tongue cancer cells by targeting BMI1. Oncogene. 31:432–445. 2012.
View Article : Google Scholar
|
|
39
|
Childs G, Fazzari M, Kung G, Kawachi N,
Brandwein-Gensler M, McLemore M, Chen Q, Burk RD, Smith RV,
Prystowsky MB, et al: Low-level expression of microRNAs let-7d and
miR-205 are prognostic markers of head and neck squamous cell
carcinoma. Am J Pathol. 174:736–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Taube JH, Malouf GG, Lu E, Sphyris N,
Vijay V, Ramachandran PP, Ueno KR, Gaur S, Nicoloso MS, Rossi S, et
al: Epigenetic silencing of microRNA-203 is required for EMT and
cancer stem cell properties. Sci Rep. 3:26872013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Heneberg P: Paracrine tumor signaling
induces transdifferentiation of surrounding fibroblasts. Crit Rev
Oncol Hematol. 97:303–311. 2016. View Article : Google Scholar
|
|
42
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar
|
|
43
|
Gillet JP and Gottesman MM: Mechanisms of
multidrug resistance in cancer. Methods Mol Biol. 596:47–76. 2010.
View Article : Google Scholar
|
|
44
|
Bourguignon LY, Wong G, Earle C and Chen
L: Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes
miR-302 expression leading to self-renewal, clonal formation, and
cisplatin resistance in cancer stem cells from head and neck
squamous cell carcinoma. J Biol Chem. 287:32800–32824. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Guerrera IC, Quetier I, Fetouchi R, Moreau
F, Vauloup-Fellous C, Lekbaby B, Rousselot C, Chhuon C, Edelman A,
Lefevre M, et al: Regulation of interleukin-6 in head and neck
squamous cell carcinoma is related to papillomavirus infection. J
Proteome Res. 13:1002–1011. 2014. View Article : Google Scholar : PubMed/NCBI
|
